Published in Sarcoma on November 03, 2013
Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol (1982) 43.81
Soft-tissue sarcomas in adults. N Engl J Med (2005) 5.97
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol (2007) 3.79
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol (2002) 3.49
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol (2005) 2.39
Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol (2005) 2.24
Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol (2004) 2.15
Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 2.00
Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer (2001) 1.99
Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol (2004) 1.69
Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. Europace (2008) 1.68
Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer (2006) 1.65
Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS) Ann Oncol (1998) 1.60
Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol (2001) 1.47
Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - a single-center experience. Onkologie (2008) 1.45
[A blood transfusion in Sweden--the societal cost]. Lakartidningen (2006) 1.41
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer (2002) 1.41
Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol (2011) 1.30
Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity. J Clin Oncol (2001) 1.26
Nonreferral of possible soft tissue sarcomas in adults: a dangerous omission in policy. Sarcoma (2009) 1.21
Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol (1994) 1.21
Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK). Ann Oncol (1998) 1.20
High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? Ann Oncol (1998) 1.19
Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ (2010) 1.17
Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer (2002) 1.16
Resource consumption and costs of palliative care services in Spain: a multicenter prospective study. J Pain Symptom Manage (2006) 1.15
Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol (2000) 1.15
Phase II trial of gemcitabine in advanced sarcomas. Cancer (2002) 1.11
Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. Br J Cancer (2009) 1.09
An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Invest New Drugs (2006) 1.08
Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer (2000) 1.08
Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain. Curr Med Res Opin (2009) 1.02
The management of soft tissue sarcoma. J Plast Reconstr Aesthet Surg (2008) 1.01
Blood loss control with two doses of tranexamic Acid in a multimodal protocol for total knee arthroplasty. Open Orthop J (2011) 0.98
Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution. Anticancer Drugs (2010) 0.96
Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study. Cancer Chemother Pharmacol (2008) 0.95
Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. Ann Oncol (2001) 0.94
Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer (2007) 0.92
Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. Anticancer Drugs (2000) 0.92
ET-743: a novel agent with activity in soft tissue sarcomas. Oncologist (2005) 0.89
Clinical benefit of second-line palliative chemotherapy in advanced soft-tissue sarcoma. Sarcoma (2010) 0.88
Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy. J Surg Oncol (2000) 0.87
Utility values for advanced soft tissue sarcoma health States from the general public in the United kingdom. Sarcoma (2013) 0.86
Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients. Sarcoma (2006) 0.86
Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden. Acta Oncol (2008) 0.86
ET-743: the US experience in sarcomas of soft tissues. Anticancer Drugs (2002) 0.85
[Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines]. Bull Cancer (2010) 0.84
Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics (2004) 0.84
Clinical and financial analysis of an acute palliative care unit in an oncological department. Palliat Med (2008) 0.84
[Epidemiology of soft tissue sarcomas in adults]. Presse Med (2001) 0.83
Low dose adriamycin and ifosfamide in the treatment of advanced adult soft tissue sarcomas. Anticancer Res (2000) 0.82
Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population. BMC Cancer (2010) 0.82
[Gemcitabine in advanced stage soft tissue sarcoma: a phase II study]. Clin Ter (1999) 0.82
Therapeutic pipeline for soft-tissue sarcoma. Expert Opin Pharmacother (2011) 0.82
Safety and efficacy of ET-743: the French experience. Anticancer Drugs (2002) 0.82
Health care costs for treatment of disseminated breast cancer. Eur J Cancer (2009) 0.81
A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma. Eur J Cancer Clin Oncol (1988) 0.81
Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective. Eur J Health Econ (2009) 0.81
Routine outcome monitoring in clinical practice: service and non-service costs of psychiatric patients attending a Community Mental Health Centre in Italy. Eur Psychiatry (2004) 0.81
The cost of treating pancreatic cancer--a cohort study based on patients' records from four hospitals in Sweden. Acta Oncol (2003) 0.81
Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen. Cancer Chemother Pharmacol (1993) 0.80
Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial. J Clin Oncol (1989) 0.80
High-dose ifosfamide in the treatment of advanced soft tissue sarcomas. Semin Oncol (1996) 0.80
Chemotherapy of soft tissue sarcoma--a clinical evaluation of treatment over ten years. Acta Oncol (2003) 0.79
Ifosfamide with and without adriamycin in advanced uterine leiomyosarcoma. Cancer Chemother Pharmacol (1990) 0.79
Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma. Cancer Chemother Pharmacol (1993) 0.79
Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma. Anticancer Drugs (1999) 0.79
Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas. Cancer Chemother Pharmacol (2006) 0.78
Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients. Tumori (2009) 0.77
Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients. Cancer Chemother Pharmacol (2009) 0.77
Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas. Anticancer Res (2003) 0.77
Multidisciplinary management of metastatic sarcoma. Surg Clin North Am (2008) 0.77
Dose-intensive chemotherapy in advanced adult soft tissue sarcoma. Expert Rev Anticancer Ther (2002) 0.77
Oral trofosfamide: an active and well-tolerated maintenance therapy for adult patients with advanced bone and soft tissue sarcomas. Results of a retrospective analysis. Onkologie (2002) 0.76
Lack of Activity of Docetaxel in Soft Tissue Sarcomas: Results of a Phase II Study of the Italian Group on Rare Tumors. Sarcoma (1999) 0.76
Modelling the resource implications of managing adults with Fabry disease in Italy. Eur J Clin Invest (2011) 0.75
PKC and the control of localized signal dynamics. Nat Rev Mol Cell Biol (2010) 2.41
Clinical outcomes and cost-effectiveness of continuous positive airway pressure to manage obstructive sleep apnea in patients with type 2 diabetes in the U.K. Diabetes Care (2014) 2.04
Cost-effectiveness of using an extensively hydrolysed formula compared to an amino acid formula as first-line treatment for cow milk allergy in the UK. Pediatr Allergy Immunol (2012) 1.65
Protein kinase C intervention: the state of play. Curr Opin Cell Biol (2009) 1.11
Health economic impact of managing patients following a community-based diagnosis of malnutrition in the UK. Clin Nutr (2011) 1.03
Control of MT1-MMP transport by atypical PKC during breast-cancer progression. Proc Natl Acad Sci U S A (2014) 0.91
Adenosine-binding motif mimicry and cellular effects of a thieno[2,3-d]pyrimidine-based chemical inhibitor of atypical protein kinase C isoenzymes. Biochem J (2013) 0.88
Utility values for advanced soft tissue sarcoma health States from the general public in the United kingdom. Sarcoma (2013) 0.86
Binding of dynein intermediate chain 2 to paxillin controls focal adhesion dynamics and migration. J Cell Sci (2012) 0.86
A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice. BMC Cancer (2014) 0.83
Utility values for chronic myelogenous leukemia chronic phase health states from the general public in the United Kingdom. Leuk Lymphoma (2011) 0.79
Reply: To PMID 23665729. J Wound Care (2013) 0.75
Cost-effectiveness of pentostatin compared with cladribine in the management of hairy cell leukemia in the United Kingdom. Clin Ther (2009) 0.75
Cost-effectiveness of using Polyheal compared with surgery in the management of chronic wounds with exposed bones and/or tendons due to trauma in France, Germany and the UK. Int Wound J (2013) 0.75
Nonsurgical oncological management of cancer pain. Curr Opin Support Palliat Care (2014) 0.75